Related Experiment Video

Updated: Jul 9, 2026

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
07:00

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

Published on: April 1, 2019

Genetic analysis of MMP gene polymorphisms in patients with Kawasaki disease

Kazuyuki Ikeda1, Kenji Ihara, Kenichiro Yamaguchi

  • 1Department of Pediatrics, Kyushu University, Fukuoka 812-8582, Japan. ikeq@pediatr.med.kyushu-u.ac.jp

Pediatric Research
|December 20, 2007
PubMed

Insights

Genetic variations in the Matrix Metalloproteinase-13 (MMP-13) gene are linked to coronary artery lesion development in Kawasaki disease (KD). This finding may aid in predicting which KD patients are at higher risk for these serious complications.

Area of Science:

  • Cardiovascular Genetics
  • Pediatric Rheumatology

Background:

  • Kawasaki disease (KD) is an acute febrile illness causing systemic vasculitis, particularly affecting coronary arteries.
  • Matrix metalloproteinases (MMPs) are implicated in the pathogenesis of coronary artery lesions (CALs) in KD patients.
  • Investigating the genetic basis of MMPs' role in CAL development is crucial for risk prediction.

Purpose of the Study:

  • To evaluate the association between functional single nucleotide polymorphisms (SNPs) in MMP genes and the formation of CALs in Kawasaki disease.
  • To identify specific MMP gene variants that may predict the development of CALs in KD patients.

Main Methods:

  • An association study was conducted on 44 KD patients with CALs, 92 KD patients without CALs, and 175 healthy controls.
  • Functional SNPs in MMP-2, MMP-3, MMP-9, MMP-12, and MMP-13 genes were analyzed.
  • Allele, genotype, and haplotype frequencies were compared between patient groups.

Main Results:

  • Significant differences in allele and genotype frequencies of the MMP-13-77A>G polymorphism were observed between KD patients with and without CALs (p = 0.00989 and p = 0.00551, respectively).
  • The G-C haplotype in the MMP-13 gene promoter was less frequent in KD patients with CALs compared to those without CALs.
  • No significant associations were found for other studied MMP gene polymorphisms (MMP-2, MMP-3, MMP-9, MMP-12) with CAL formation.

Conclusions:

  • The MMP-13 gene, specifically the -77A>G polymorphism, is associated with the development of coronary artery lesions in Kawasaki disease.
  • Genetic evaluation of MMP-13 may contribute to predicting CAL formation in KD patients.
  • Further research is warranted to elucidate the precise mechanisms by which MMP-13 influences KD vasculitis.

More Related Videos

Digital Polymerase Chain Reaction Assay for the Genetic Variation in a Sporadic Familial Adenomatous Polyposis Patient Using the Chip-in-a-tube Format05:58

Digital Polymerase Chain Reaction Assay for the Genetic Variation in a Sporadic Familial Adenomatous Polyposis Patient Using the Chip-in-a-tube Format

Published on: August 20, 2018

Related Concept Videos

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Genome-wide Association Studies-GWAS01:11

Genome-wide Association Studies-GWAS

Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Single Nucleotide Polymorphisms-SNPs01:05

Single Nucleotide Polymorphisms-SNPs

A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...